Wednesday, October 20, 2021 10:19:06 AM
Here's a quote from TGD at the H.C. Wainwright 23rd Annual Global Investment Conference last month...at the 12:40 minute mark:
"But the most important distinction of A2-73 and the entire platform of sigma-1 activation is that we've now been able to learn, very recently, that sigma-1 activation goes even further upstream into the nucleus...and its been able to show that it prevents cellular stress before and after RNA translation.
So in regards to that, chromatin remodeling is restored, as well as post-translation proteins - which are toxic - are prevented, by preventing toxic RNA to be expressed into toxic proteins. So only healthy proteins are expressed by expressing healthy RNA".
https://journey.ct.events/view/48684630-6af2-4c12-a206-f94233cde440
powerful stuff-observation, IMO. I also often think about the PDD "stop the action" "late breaking" FDA moment in LA months ago, then NADA-zippo..a giant "So WHAT" moment. HUH, these pieces among others do not yet fit into the current status quo. Regulatory bodies do not do such things unless they have a good reason.
This kinda fits w/my own sense that our period of AVXL top down silent observation must be tied to FDA discussions. Even if we have our issues w/their 30+ year Amyloid giant dead end that are unresolved , unless they can work a deal w/AVXL that allows for them to retain a level of credibility while the science moves forward. IMO, there are serious (but not yet fatal) consequences to all this that must be worked out. (FDA live in a time-space continuum different than the rest of us). That is what will continue until a way out can be agreed. ALL IMO.
Once the management cliff hanger is worked out then ..."stand back" a bunch of new science-trial information and plans can be made public. We are in this up to our eyeballs and FDA-(other WW regulatory bodies) are awaiting the all clear-launch signal.
Would like to speculate also that FDA have learned that politics and medical science should not ever be mixed, reactions can be extreme and explosive. I guess we will know it when we see it b/c this will be a different kind of process news which will/should allow-promote win-wins.
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
